GSA Capital Partners LLP Has $2.87 Million Stock Holdings in Arcus Biosciences, Inc. (NYSE:RCUS)

GSA Capital Partners LLP boosted its stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS) by 17.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 187,415 shares of the company’s stock after purchasing an additional 28,307 shares during the period. GSA Capital Partners LLP owned 0.20% of Arcus Biosciences worth $2,866,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in RCUS. Vanguard Group Inc. lifted its holdings in Arcus Biosciences by 2.4% during the 1st quarter. Vanguard Group Inc. now owns 4,791,244 shares of the company’s stock worth $90,459,000 after purchasing an additional 110,528 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in Arcus Biosciences by 8.7% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 744,298 shares of the company’s stock worth $11,336,000 after acquiring an additional 59,273 shares during the period. SG Americas Securities LLC increased its stake in Arcus Biosciences by 1,396.1% during the 2nd quarter. SG Americas Securities LLC now owns 129,292 shares of the company’s stock worth $1,969,000 after acquiring an additional 120,650 shares during the period. Cubist Systematic Strategies LLC bought a new position in shares of Arcus Biosciences in the 2nd quarter valued at $1,286,000. Finally, The Manufacturers Life Insurance Company grew its position in Arcus Biosciences by 7.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,858 shares of the company’s stock worth $455,000 after acquiring an additional 2,123 shares during the last quarter. 92.89% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the company. Barclays lifted their target price on Arcus Biosciences from $25.00 to $29.00 and gave the stock an “overweight” rating in a report on Friday, October 25th. Wells Fargo & Company initiated coverage on Arcus Biosciences in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $29.00 price objective on the stock. Cantor Fitzgerald reissued an “overweight” rating on shares of Arcus Biosciences in a research note on Thursday, October 3rd. Wedbush reissued an “outperform” rating and issued a $36.00 price objective on shares of Arcus Biosciences in a research note on Thursday, November 7th. Finally, Evercore ISI raised Arcus Biosciences to a “strong-buy” rating in a research note on Friday, August 9th. One analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $34.13.

Arcus Biosciences Stock Performance

Shares of RCUS opened at $17.74 on Tuesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 5.14 and a current ratio of 5.24. The stock has a 50 day moving average price of $16.62 and a two-hundred day moving average price of $16.09. The firm has a market capitalization of $1.62 billion, a P/E ratio of -5.63 and a beta of 0.89. Arcus Biosciences, Inc. has a 52 week low of $12.95 and a 52 week high of $20.31.

Arcus Biosciences (NYSE:RCUS) last released its earnings results on Wednesday, November 6th. The company reported ($1.00) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.06. The company had revenue of $48.00 million during the quarter, compared to analyst estimates of $38.95 million. Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. Arcus Biosciences’s quarterly revenue was up 50.0% on a year-over-year basis. During the same period in the prior year, the company posted ($0.94) earnings per share. Equities analysts forecast that Arcus Biosciences, Inc. will post -3.25 earnings per share for the current fiscal year.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.